Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-509 in active rheumatoid arthritis
2009-017438-32Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of decernotinib in rheumatoid arthritis (RA) (5 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: ACR20 response at Week 12. Started Feb 2010; status: completed.
02
Drugs
decernotinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2009-017438-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017438-32.